安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Imuldosa: Uses, Dosage, Side Effects, Warnings - Drugs. com
Imuldosa (ustekinumab-srlf) is an injectable prescription medicine which is a biosimilar to Stelara that may be used to treat certain types of plaque psoriasis, active psoriatic arthritis, Crohn’s disease, and ulcerative colitis, which are all autoimmune conditions
- Imuldosa (Ustekinumab-srlf Injection for Subcutaneous or . . . - RxList
Our Imuldosa (ustekinumab-srlf) Injection, for Subcutaneous or Intravenous Use Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication
- label - accordbiopharma. com
IMULDOSA is indicated for the treatment of adults and pediatric patients 6 years of age and older with active psoriatic arthritis IMULDOSA is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease
- label - accessdata. fda. gov
IMULDOSA is a medicine that affects your immune system IMULDOSA can increase your risk of having serious side effects, including: Serious infections IMULDOSA may lower the ability of your
- imuldosa. com - ARE YOU A HEALTHCARE PROFESSIONAL?
ARE YOU A HEALTHCARE PROFESSIONAL? The information provided in this website is intended for US healthcare professionals only I confirm I am a US healthcare professional We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits
- FDA Approves Imuldosa, Stelara Biosimilar For Treatment of Chronic . . .
Clinical trials confirmed Imuldosa's similarity to Stelara in pharmacokinetics, safety, tolerability, and efficacy, adhering to FDA biosimilar guidelines Imuldosa provides an affordable treatment alternative, enhancing Accord BioPharma's position in offering accessible healthcare solutions
- IMULDOSA- ustekinumab-srlf injection - DailyMed
1 1 Plaque Psoriasis (PsO) IMULDOSA is indicated for the treatment of adults and pediatric patients 6 years of age and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy
- FDA Approves IMULDOSA™ (ustekinumab-srlf), Accord BioPharmas . . .
With the approval of IMULDOSA, Accord BioPharma's biosimilar portfolio continues to grow while expanding treatment options appropriate for patients
|
|
|